Recruiting

Trial ID CA209-8TT | NCT03899155

Pan Tumor Rollover Study

About This Trial
Key Eligibility Criteria
Trial Site Locations

Summary

Phase 2
18+

Age Range
156

Locations
Recruiting

Overview

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Signed Written Informed Consent.
Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

Exclusion Criteria

Participant is not eligible for study treatment per the Parent Study eligibility criteria.
Participants not receiving clinical benefit as assessed by the Investigator.
Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
Other protocol-defined Inclusion/Exclusion Criteria apply

Additional Information *

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: A1: Nivolumab Monotherapy Dose 1

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: A2: Nivolumab Monotherapy Dose 2

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: B1: Nivolumab + Ipilimumab

ASSIGNED INTERVENTION

Drug: Ipilimumab, Nivolumab

Study Arms

Experimental: B2: Nivolumab + Ipilimumab + Cabozantinib

ASSIGNED INTERVENTION

Drug: Ipilimumab, Cabozantinib, Nivolumab

Study Arms

Experimental: B3: Nivolumab + Ipilimumab + Trametinib

ASSIGNED INTERVENTION

Drug: Ipilimumab, Trametinib, Nivolumab

Study Arms

Experimental: C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab

Study Arms

Experimental: C10: Relatlimab + Nivolumab SAV Dose 4

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C11: Relatlimab + Nivolumab SAV + PDCT Dose 2

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C12: Relatlimab + Nivolumab SAV Dose 5

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab

Study Arms

Experimental: C4: Relatlimab + Nivolumab SAV Dose 2

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C5: Relatlimab + Nivolumab + Ipilimumab

ASSIGNED INTERVENTION

Drug: Ipilimumab, Nivolumab

Study Arms

Experimental: C6: Relatlimab + Nivolumab + Capecitabine

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab, Capecitabine

Study Arms

Experimental: C7: Relatlimab + Nivolumab SAV Dose 3

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C8: Relatlimab + Nivolumab SAV + PDCT Dose 1

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C9: Relatlimab + Nivolumab SAV + Bevacizumab

ASSIGNED INTERVENTION

Drug: Relatlimab, Bevacizumab, Nivolumab

Study Arms

Experimental: D1: Nivolumab + Temozolomide

ASSIGNED INTERVENTION

Drug: Temozolomide, Nivolumab

Study Arms

Experimental: D2: Nivolumab + Rucaparib

ASSIGNED INTERVENTION

Drug: Rucaparib, Nivolumab

Study Arms

Experimental: D3: Nivolumab + Daratumumab

ASSIGNED INTERVENTION

Drug: Daratumumab, Nivolumab

Study Arms

Experimental: D4: Nivolumab + Bevacizumab

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: E1: Bevacizumab Monotherapy

ASSIGNED INTERVENTION

Drug: Bevacizumab

Study Arms

Experimental: E10: Pemetrexed Monotherapy

ASSIGNED INTERVENTION

Drug: Pemetrexed

Study Arms

Experimental: E11: Pembrolizumab Monotherapy

ASSIGNED INTERVENTION

Drug: Pembrolizumab

Study Arms

Experimental: E2: Regorafinib Monotherapy

ASSIGNED INTERVENTION

Drug: Regorafinib

Study Arms

Experimental: E3: Leucovorin + Fluorouracil

ASSIGNED INTERVENTION

Drug: Leucovorin

Study Arms

Experimental: E4: Leucovorin + Oxaliplatin + Fluorouracil

ASSIGNED INTERVENTION

Drug: Leucovorin, Fluorouracil, Oxaliplatin

Study Arms

Experimental: E5: Enzalutamide Monotherapy

ASSIGNED INTERVENTION

Drug: Enzalutamide

Study Arms

Experimental: E6: Sunitinib Monotherapy

ASSIGNED INTERVENTION

Drug: Sunitinib

Study Arms

Experimental: E7: Rucaparib Monotherapy

ASSIGNED INTERVENTION

Drug: Rucaparib

Study Arms

Experimental: E8: Capecitabine Monotherapy

ASSIGNED INTERVENTION

Drug: Capecitabine

Study Arms

Experimental: E9: Cabozantinib Monotherapy

ASSIGNED INTERVENTION

Drug: Cabozantinib

Please select a study site to register

Select a Study Site Location

Select a study site location that is convenient for you

Provide your contact details for the study site to connect with you.

Trial ID CA209-8TT | NCT03899155

Summary

Overview

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you